0001104659-23-090511.txt : 20230811 0001104659-23-090511.hdr.sgml : 20230811 20230811163038 ACCESSION NUMBER: 0001104659-23-090511 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230809 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Theriva Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12584 FILM NUMBER: 231164570 BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: Synthetic Biologics, Inc. DATE OF NAME CHANGE: 20120305 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 8-K 1 tm2323521d1_8k.htm FORM 8-K
0000894158 false --12-31 0000894158 2023-08-09 2023-08-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 9, 2023

 

THERIVA BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-12584   13-3808303

(State or other jurisdiction of

incorporation)

   (Commission File No.)  

(IRS Employer Identification

No.)

 

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

(Address of principal executive offices and zip code)

 

(301) 417-4364

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share TOVX NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.03.  Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On August 9, 2023, the Board of Directors (the “Board”) of Theriva Biologics, Inc., a Nevada corporation (the “Company”) amended and restated the Company’s amended and restated bylaws (the “Bylaws”), effective October 3, 2023. The Bylaws include new provisions related to advance notice procedures.

  

Section 1.11 sets forth advance notice procedures for director nominations and other stockholder proposals. Stockholders seeking to nominate candidates for election as directors at or bring other business before an annual or special meeting of stockholders must provide timely notice thereof in writing. To be timely, stockholders who wish to directly recommend candidates for election to the Board at an annual meeting must give written notice to the Chairman of the Nominations Committee, which notice shall be delivered not less than 120 days prior to the anniversary of the preceding year’s annul meeting. Stockholders who wish to bring other proposals before an annual meeting must give written notice to the Secretary of the Company, which notice shall be delivered not less than 120 days prior to the anniversary of the preceding year’s annual meeting to be considered timely. Such stockholders’ notice must comply with the various requirements set forth in paragraphs (c) and (e) of Section 1.11, as applicable.

 

The foregoing description is qualified in its entirety by the Bylaws which are attached hereto as Exhibit 3.1 and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)   Exhibits.

 

Exhibit
Number		   Description
3.1   Second Amended and Restated Bylaws of Theriva Biologics, Inc.
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 11, 2023 THERIVA BIOLOGICS, INC.
       
  By: /s/ Steven A. Shallcross
    Name:  Steven A. Shallcross
    Title: Chief Executive Officer and Chief Financial Officer

  

 

 

 EX-3.1 2 tm2323521d1_ex3-1.htm EXHIBIT 3.1

 

Exhibit 3.1 

 

SECOND AMENDED AND RESTATED BY-LAWS

 

OF

 

THERIVA BIOLOGICS, INC.

 

(a Nevada corporation)

 

Adopted: August 9, 2023

Effective:  October 3, 2023

 

ARTICLE 1

 

STOCKHOLDERS

 

1.01   Annual Meetings. An annual meeting of stockholders shall be held for the election of Directors at such date, time and place either within or without the State of Nevada as may be designated by the Board of Directors from time to time. Any other proper business may be transacted at the annual meeting.

 

1.02  Special Meetings. Special meetings of stockholders may be called at any time by the Chairman of the Board, if any, the Vice Chairman of the Board, if any, or the President to be held at such date, time and place either within or without the State of Nevada as may be stated in the notice of the meeting. A special meeting of stockholders shall be called by the Secretary within 120 days of his or her receipt of a written request, stating the purpose of the meeting, of stockholders who together own of record a majority of the outstanding shares of each class of stock entitled to vote at such meeting.

 

1.03   Notice of Meetings. Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise provided by law, the written notice of any meeting shall be given not less than ten nor more than sixty days before the date of the meeting to each stockholder entitled to vote at such meeting. If mailed, such notice shall be deemed to be given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the Corporation.

 

1.04   Adjournments. Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene at the same or some other place, and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.

 

1.05   Quorum. At each meeting of stockholders, except where otherwise provided by law, the presence in person or by proxy of the holders of shares of stock having one-third (1/3) of the voting power of the shares of stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. In the absence of a quorum the stockholders so present may, by majority vote, adjourn the meeting from time to time in the manner provided by Section 1.04 of these by-laws until a quorum shall attend. Shares of its own capital stock belonging on the record date for the meeting to the Corporation or to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation is held, directly or indirectly, by the Corporation, shall neither be entitled to vote nor be counted for quorum purposes; provided, however, that the foregoing shall not limit the right of the Corporation to vote stock, including but not limited to its own stock, held by it in a fiduciary capacity.

 

1.06   Organization. Meetings of stockholders shall be presided over by the Chairman of the Board, if any, or in the absence of the Chairman of the Board by the Vice Chairman of the Board, if any, or in the absence of the Vice Chairman of the Board by the President, or in the absence of the President by a Vice President, or in the absence of the foregoing persons by a chairman designated by the Board of Directors, or in the absence of such designation by a chairman chosen at the meeting. The Secretary, or in the absence of the Secretary an Assistant Secretary, shall act as secretary of the meeting, but in the absence of the Secretary and any Assistant Secretary the chairman of the meeting may appoint any person to act as secretary of the meeting. 

 

 

 

 

1.07   Voting; Proxies. Unless otherwise provided in the articles of incorporation, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of stock held by such stockholder which has voting power upon the matter in question. If the articles of incorporation provides for more or less than one vote for any share on any matter, every reference in these by-laws to a majority or other proportion of stock shall refer to such majority or other proportion of the votes of such stock. Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A duly executed proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by filing an instrument in writing revoking the proxy or another duly executed proxy bearing a later date with the Secretary of the Corporation. Voting at meetings of stockholders need not be by written ballot and need not be conducted by inspectors unless the holders of a majority of the outstanding shares of all classes of stock entitled to vote thereon present in person or by proxy at such meeting shall so determine. At all meetings of stockholders for the election of directors a plurality of the votes cast shall be sufficient to elect. With respect to other matters, unless otherwise provided by law or by the articles of incorporation or these by-laws, the affirmative vote of the holders of a majority of the shares of all classes of stock present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders, provided that (except as otherwise required by law or by the articles of incorporation) the Board of Directors may require a larger vote upon any such matter. Where a separate vote by class is required, the affirmative vote of the holders of a majority of the shares of each class present in person or represented by proxy at the meeting shall be the act of such class, except as otherwise provided by law or by the articles of incorporation or these by-laws.

 

1.08   Fixing Date for Determination of Stockholders of Record. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not be more than sixty nor less than ten days before the date of such meeting, nor more than sixty days prior to any other action. If no record date is fixed: (1) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; (2) the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting, when no prior action by the Board is necessary, shall be the day on which the first written consent is expressed; and (3) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for the adjourned meeting.

 

1.09   List of Stockholders Entitled to Vote. The Secretary shall prepare and make, at least ten days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is present.

 

1.10   Consent of Stockholders in Lieu of Meeting. Any action required by law to be taken at any annual or special meeting of stockholders of the Corporation, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.

 

 

 

 

1.11    Notice Requirements for Director Nominations and Stockholder Proposals.

 

(a)            Only persons who are nominated in accordance with the procedures set forth in these Second Amended and Restated Bylaws (the “Bylaws”) shall be eligible to serve as directors.  Nominations of persons for election to the Board of Directors of the Corporation may be made at a meeting of stockholders (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the Corporation who is a stockholder of record at the time of giving of notice provided for in this Section 1.11, who is entitled to vote for the election of directors at the meeting and who complies with the notice procedures set forth in this Section 1.11.

 

(b)            Stockholders wishing to directly recommend candidates for election to the Board of Directors at an annual meeting must do so by giving notice in writing to the Chairman of the Nominations Committee at the principal executive office of the Corporation. Any such notice must, for any given annual meeting, be delivered to the Chairman of the Nominations Committee not less than 120 days prior to the anniversary of the preceding year's annual meeting; provided, however, that in the event that the date of the annual meeting is changed by more than 30 days from such anniversary date, notice by the stockholder to be timely must be so received not later than the close of business on the tenth day following the earlier of the day on which notice of the date of the meeting was mailed or public disclosure was made; and (ii) in the case of a special meeting at which directors are to be elected, not later than the close of business on the tenth day following the earlier of the day on which notice of the date of the meeting was mailed or public disclosure was made.

 

(c)            Such stockholder’s notice pursuant to paragraph (b) of this Section 1.11 must state (1) the name and address of the stockholder making the recommendations, (2) the name, age, business address, and residential address of each person recommended, (3) the principal occupation or employment of each person recommended, (4) the class and number of shares of the Corporation that are beneficially owned by each person recommended and by the recommending stockholder, (5) any other information concerning the persons recommended that must be disclosed in nominee and proxy solicitations in accordance with Regulation 14A of the Securities Exchange Act of 1934, as amended, and, (6) a signed consent of each person recommended stating that he or she consents to serve as a director of the Corporation if elected.

 

(d)            At an annual meeting of the stockholders, only such business shall be conducted as shall have been brought before the meeting (i) pursuant to the Corporation’s Notice of Annual Meeting of Stockholders, (ii) by or at the direction of the Board of Directors or (iii) by any stockholder of the Corporation who is a stockholder of record at the time of giving of the notice provided for in this Section 1.11, who is entitled to vote at such meeting and who complies with the notice procedures set forth in paragraph (e) of this Section 1.11.

 

(e)            For business to be properly brought before an annual meeting by a stockholder pursuant to clause (iii) of paragraph (d) of this Section 1.11, the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation at the principal executive office of the Corporation. To be timely, a stockholder’s notice must be delivered to or mailed and received at the principal executive office of the Corporation not less than 120 days prior to the anniversary of the preceding year's annual meeting; provided, however, that in the event that the date of the meeting is changed by more than 30 days from such anniversary date, to be timely, notice by the stockholder must be received no later than the close of business on the tenth day following the earlier of the day on which notice of the date of the meeting was mailed or public disclosure was made.  A stockholder’s notice to the Secretary shall set forth as to each matter the stockholder proposes to bring before the meeting: (i) a brief description of the business desired to be brought before the meeting and the reasons for conducting such business at the meeting; (ii) the name and address, as they appear on the Corporation’s books, of the stockholder proposing such business, and the name and address of the beneficial owner, if any, on whose behalf the proposal is made; (iii) the class and number of shares of the Corporation which are owned beneficially and of record by such stockholder of record and by the beneficial owner, if any, on whose behalf the proposal is made; and (iv) any material interest of such stockholder of record and the beneficial owner, if any, on whose behalf the proposal is made in such business.

 

 

 

 

(f)            Notwithstanding anything in these Bylaws to the contrary, no business shall be conducted at an annual meeting except in accordance with the procedures set forth in this Section 1.11.  Additionally, no person shall be eligible to serve as a director of the Corporation unless nominated in accordance with the procedures set forth in this Section 1.11.  The chairman of the meeting shall, if the facts warrant, determine and declare to the meeting that (i) the business was not properly brought before the meeting and in accordance with the procedures prescribed by this Section 1.11 or (ii) a nomination was not made in accordance with the procedures prescribed by these Bylaws.  If the chairman of the meeting should so determine, he or she shall so declare to the meeting, and any such business not properly brought before the meeting shall not be transacted or the defective nomination shall be disregarded.  Notwithstanding the foregoing provisions of this Section 1.11, a stockholder shall also comply with all applicable requirements of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder with respect to the matters set forth in this Section 1.11.

 

ARTICLE 2

 

BOARD OF DIRECTORS

 

2.01   Powers; Number; Qualifications. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided by law or in the articles of incorporation. The Board shall consist of one or more members, the number thereof to be determined from time to time by the Board. Directors need not be stockholders.

 

2.02   Election; Term of Office; Resignation; Removal; Vacancies. Each director shall hold office until the annual meeting of stockholders next succeeding his or her election and until his or her successor is elected and qualified or until his or her earlier resignation or removal. Any director may resign at any time upon written notice to the Board of Directors or to the President or the Secretary of the Corporation. Such resignation shall take effect at the time specified therein, and unless otherwise specified therein no acceptance of such resignation shall be necessary to make it effective. Any director or the entire Board of Directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors; except that, if the articles of incorporation provides for cumulative voting and less than the entire Board is to be removed, no director may be removed without cause if the votes cast against his or her removal would be sufficient to elect him or her if then cumulatively voted at an election of the entire Board, or, if there be classes of directors, at an election of the class of directors of which he or she is a part. Whenever the holders of any class or series of stock are entitled to elect one or more directors by the provisions of the articles of incorporation, the provisions of the preceding sentence shall apply, in respect to the removal without cause of a director or directors so elected, to the vote of the holders of the outstanding shares of that class or series and not to the vote of the outstanding shares as a whole. Unless otherwise provided in the articles of incorporation or these by-laws, vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class or from any other cause may be filled by a majority of the directors then in office, although less than a quorum, or by the sole remaining director. Whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the articles of incorporation, vacancies and newly created directorships of such class or classes or series may be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by the sole remaining director so elected.

 

2.03   Regular Meetings. Regular meetings of the Board of Directors may be held at such places within or without the State of Nevada and at such times as the Board may from time to time determine, and if so determined notice thereof need not be given.

 

2.04   Special Meetings. Special meetings of the Board of Directors may be held at any time or place within or without the State of Nevada whenever called by the Chairman of the Board, if any, by the Vice Chairman of the Board, if any, by the President or by any two directors. Reasonable notice thereof shall be given by the person or persons calling the meeting.

 

 

 

 

2.05   Participation in Meetings by Conference Telephone Permitted. Unless otherwise restricted by the articles of incorporation or these by-laws, members of the Board of Directors, or any committee designated by the Board, may participate in a meeting of the Board or of such committee, as the case may be, by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this by-law shall constitute presence in person at such meeting.

 

2.06   Quorum; Vote Required for Action. At all meetings of the Board of Directors one-third of the entire Board shall constitute a quorum for the transaction of business. The vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board unless the articles of incorporation or these by-laws shall require a vote of a greater number. In case at any meeting of the Board a quorum shall not be present, the members of the Board present may adjourn the meeting from time to time until a quorum shall attend.

 

2.07   Organization. Meetings of the Board of Directors shall be presided over by the Chairman of the Board, if any, or in the absence of the Chairman of the Board by the Vice Chairman of the Board, if any, or in the absence of the Vice Chairman of the Board by the President, or in their absence by a chairman chosen at the meeting. The Secretary, or in the absence of the Secretary an Assistant Secretary, shall act as secretary of the meeting, but in the absence of the Secretary and any Assistant Secretary the chairman of the meeting may appoint any person to act as secretary of the meeting.

 

2.08   Action by Directors Without a Meeting. Any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board or of such committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board or committee.

 

2.09   Compensation of Directors. The Board of Directors shall have the authority to fix the compensation of directors.

 

ARTICLE 3

 

COMMITTEES

 

3.01   Committees. The Board of Directors may, by resolution passed by a majority of the whole Board, designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it; but no such committee shall have power or authority in reference to amending the articles of incorporation, adopting an agreement of merger or consolidation, recommending to the stockholders the sale, lease or exchange of all or substantially all of the Corporation’s property and assets, recommending to the stockholders a dissolution of the Corporation or a revocation of dissolution, removing or indemnifying directors or amending these by-laws; and, unless the resolution expressly so provides, no such committee shall have the power or authority to declare a dividend or to authorize the issuance of stock.

 

3.02   Committee Rules. Unless the Board of Directors otherwise provides, each committee designated by the Board may adopt, amend and repeal rules for the conduct of its business. In the absence of a provision by the Board or a provision in the rules of such committee to the contrary, a majority of the entire authorized number of members of such committee shall constitute a quorum for the transaction of business, the vote of a majority of the members present at a meeting at the time of such vote if a quorum is then present shall be the act of such committee, and in other respects each committee shall conduct its business in the same manner as the Board conducts its business pursuant to Article II of these by-laws.

 

 

 

 

ARTICLE 4

 

OFFICERS

 

4.01   Officers; Election. As soon as practicable after the annual meeting of stockholders in each year, the Board of Directors shall elect a President and a Secretary, and it may, if it so determines, elect from among its members a Chairman of the Board and a Vice Chairman of the Board.

 

4.02   The Board may also elect one or more Vice Presidents, one or more Assistant Vice Presidents, one or more Assistant Secretaries, a Treasurer and one or more Assistant Treasurers and such other officers as the Board may deem desirable or appropriate and may give any of them such further designations or alternate titles as it considers desirable. Any number of offices may be held by the same person.

 

4.03   Term of office; Resignation; Removal; Vacancies. Except as otherwise provided in the resolution of the Board of Directors electing any officer, each officer shall hold office until the first meeting of the Board after the annual meeting of stockholders next succeeding his or her election, and until his or her successor is elected and qualified or until his or her earlier resignation or removal. Any officer may resign at any time upon written notice to the Board or to the President or the Secretary of the Corporation. Such resignation shall take effect at the time specified therein, and unless otherwise specified therein no acceptance of such resignation shall be necessary to make it effective. The Board may remove any officer with or without cause at any time. Any such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation, but the election of an officer shall not of itself create contractual rights. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled for the unexpired portion of the term by the Board at any regular or special meeting.

 

4.04   Chairman of the Board. The Chairman of the Board, if any, shall preside at all meetings of the Board of Directors and of the stockholders at which he or she shall be present and shall have and may exercise such powers as may, from time to time, be assigned to him or her by the Board and as may be provided by law.  The Chairman of the Board may be, but also need not be, an officer of the Corporation or employed in an executive or any other capacity by the Corporation.

 

4.05   Vice Chairman of the Board. In the absence of the Chairman of the Board, the Vice Chairman of the Board, if any, shall preside at all meetings of the Board of Directors and of the stockholders at which he or she shall be present and shall have and may exercise such powers as may, from time to time, be assigned to him or her by the Board and as may be provided by law.

 

4.06   President. In the absence of the Chairman of the Board and Vice Chairman of the Board, the President shall preside at all meetings of the Board of Directors and of the stockholders at which he or she shall be present. The President shall be the chief executive officer and shall have general charge and supervision of the business of the Corporation and, in general, shall perform all duties incident to the office of president of a corporation and such other duties as may, from time to time, be assigned to him or her by the Board or as may be provided by law.

 

4.07   Vice Presidents. The Vice President or Vice Presidents, at the request or in the absence of the President or during the President’s inability to act, shall perform the duties of the President, and when so acting shall have the powers of the President. If there be more than one Vice President, the Board of Directors may determine which one or more of the Vice Presidents shall perform any of such duties; or if such determination is not made by the Board, the President may make such determination; otherwise any of the Vice Presidents may perform any of such duties. The Vice President or Vice Presidents shall have such other powers and shall perform such other duties as may, from time to time, be assigned to him or her or them by the Board or the President or as may be provided by law.

 

4.08   Secretary. The Secretary shall have the duty to record the proceedings of the meetings of the stockholders, the Board of Directors and any committees in a book to be kept for that purpose, shall see that all notices are duly given in accordance with the provisions of these by-laws or as required by law, shall be custodian of the records of the Corporation, may affix the corporate seal to any document the execution of which, on behalf of the Corporation, is duly authorized, and when so affixed may attest the same, and, in general, shall perform all duties incident to the office of secretary of a corporation and such other duties as may, from time to time, be assigned to him or her by the Board or the President or as may be provided by law.

 

 

 

 

4.09   Treasurer. The Treasurer shall have charge of and be responsible for all funds, securities, receipts and disbursements of the Corporation and shall deposit or cause to be deposited, in the name of the Corporation, all moneys or other valuable effects in such banks, trust companies or other depositories as shall, from time to time, be selected by or under authority of the Board of Directors. If required by the Board, the Treasurer shall give a bond for the faithful discharge of his or her duties, with such surety or sureties as the Board may determine. The Treasurer shall keep or cause to be kept full and accurate records of all receipts and disbursements in books of the Corporation, shall render to the President and to the Board, whenever requested, an account of the financial condition of the Corporation, and, in general, shall perform all the duties incident to the office of treasurer of a corporation and such other duties as may, from time to time, be assigned to him or her by the Board or the President or as may be provided by law.

 

4.10   Other Officers. The other officers, if any, of the Corporation shall have such powers and duties in the management of the Corporation as shall be stated in a resolution of the Board of Directors which is not inconsistent with these by-laws and, to the extent not so stated, as generally pertain to their respective offices, subject to the control of the Board. The Board may require any officer, agent or employee to give security for the faithful performance of his or her duties.

 

ARTICLE 5

 

STOCK

 

5.01   Certificates. Every holder of stock in the Corporation shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairman or Vice Chairman of the Board of Directors, if any, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, certifying the number of shares owned by such holder in the Corporation. If such certificate is manually signed by one officer or manually countersigned by a transfer agent or by a registrar, any other signature on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.

 

5.02   Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates. The Corporation may issue a new certificate of stock in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.

 

ARTICLE 6

 

MISCELLANEOUS

 

6.01   Fiscal Year. The fiscal year of the Corporation shall be determined by the Board of Directors.

 

6.02   Seal. The Corporation may have a corporate seal which shall have the name of the Corporation inscribed thereon and shall be in such form as may be approved from time to time by the Board of Directors. The corporate seal may be used by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.

 

6.03   Waiver of Notice of Meetings of Stockholders, Directors and Committees. Whenever notice is required to be given by law or under any provision of the articles of incorporation or these by-laws, a written waiver thereof, signed by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors, or members of a committee of directors need be specified in any written waiver of notice unless so required by the articles of incorporation or these by-laws.

 

 

 

 

6.04   Indemnification of Directors, Officers and Employees. The Corporation shall indemnify to the full extent authorized by law any person made or threatened to be made a party to any action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that such person or such person’s testator or intestate is or was a director, officer or employee of the Corporation or serves or served at the request of the Corporation any other enterprise as a director, officer or employee. For purposes of this by-law, the term Corporation” shall include any predecessor of the Corporation and any constituent corporation (including any constituent of a constituent) absorbed by the Corporation in a consolidation or merger; the term ‘other enterprise‘ shall include any corporation, partnership, joint venture, trust or employee benefit plan; service ‘at the request of the Corporation‘ shall include service as a director, officer or employee of the Corporation which imposes duties on, or involves services by, such director, officer or employee with respect to an employee benefit plan, its participants or beneficiaries; any excise taxes assessed on a person with respect to an employee benefit plan shall be deemed to be indemnifiable expenses; and action by a person with respect to an employee benefit plan which such person reasonably believes to be in the interest of the participants and beneficiaries of such plan shall be deemed to be action not opposed to the best interests of the Corporation. 

 

6.05   Interested Directors; Quorum. No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract or transaction, or solely because his or her or their votes are counted for such purpose, if: (1) the material facts as to his or her relationship or interest and as to the contract or transaction are disclosed or are known to the Board or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or (2) the material facts as to his or her relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or (3) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified, by the Board, a committee thereof or the stockholders. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board or of a committee which authorizes the contract or transaction.

 

6.06   Form of Records. Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account and minute books, may be kept on, or be in the form of, punch cards, magnetic tape, photographs, microphotographs or any other information storage device, provided that the records so kept can be converted into clearly legible form within a reasonable time. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect the same.

 

6.07   Amendment of By-Laws. These by-laws may be amended or repealed, and new by-laws adopted, by the Board of Directors, but the stockholders entitled to vote may adopt additional by-laws and may amend or repeal any by-laws whether adopted by them or otherwise.

 

 

 

 EX-101.SCH 3 syn-20230809.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 syn-20230809_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 syn-20230809_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 09, 2023
Current Fiscal Year End Date --12-31
Entity File Number 001-12584
Entity Registrant Name THERIVA BIOLOGICS, INC.
Entity Central Index Key 0000894158
Entity Tax Identification Number 13-3808303
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 9605 Medical Center Drive
Entity Address, Address Line Two Suite 270
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 417-4364
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol TOVX
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 7 tm2323521d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000894158 2023-08-09 2023-08-09 iso4217:USD shares iso4217:USD shares 0000894158 false --12-31 8-K 2023-08-09 THERIVA BIOLOGICS, INC. NV 001-12584 13-3808303 9605 Medical Center Drive Suite 270 Rockville MD 20850 301 417-4364 false false false false Common stock, par value $0.001 per share TOVX NYSEAMER false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " 9,0 !X;"]W M;W)K8F]O:RYX;6Q02P$"% ,4 " #3@PM7)!Z;HJT #X 0 &@ M @ 'S$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " #3@PM799!YDAD! #/ P $P @ '8$@ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" B% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://syntheticbiologics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2323521d1_8k.htm syn-20230809.xsd syn-20230809_lab.xml syn-20230809_pre.xml tm2323521d1_ex3-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2323521d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2323521d1_8k.htm" ] }, "labelLink": { "local": [ "syn-20230809_lab.xml" ] }, "presentationLink": { "local": [ "syn-20230809_pre.xml" ] }, "schema": { "local": [ "syn-20230809.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "syn", "nsuri": "http://syntheticbiologics.com/20230809", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323521d1_8k.htm", "contextRef": "AsOf2023-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://syntheticbiologics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323521d1_8k.htm", "contextRef": "AsOf2023-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-090511-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-090511-xbrl.zip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